Skip to Menu Skip to Search Contact Us Global Websites & Languages Skip to Content

SGS, a leading biopharmaceutical analytical and bioanalytical contract solutions provider, today announced that it is investing €3.5 million to undertake a two-phase expansion project at its laboratory in Poitiers, France, to implement a 50% increase in bioanalytical capabilities at the site by 2020.

The initial phase of the project was completed in November 2018, with the delivery of a new, 150 sq. meter immunoassay laboratory, equipped with 8 instruments (MSD, ELISA, Luminex, Ella) and with the capacity to employ 20 analysts.

The second phase of the expansion will commence with the construction of a new, 800 sq. meter building, housing both a new laboratory and office space, and the renovation of the existing laboratory at the site. Alongside the renovation works will be the introduction of a new electronic laboratory notebook system across the entire facility, as well as upgrades to the site's quality management system and sample automation capabilities.

Recruitment of new staff, which has seen an increase of over 25% over the past two years, is set to continue and will further accelerate by Q3 2019.

Alain Renoux, Laboratory Director, said: "This major investment in equipment, facilities and expert staff will significantly increase the capabilities at the site to match increasing demand and shorten processes for our pharmaceutical clients. SGS has a commitment to offer a global presence with a center of excellence model, and it is through investment in both the state-of-the-art facilities and staff that we can meet this ambition."

SGS's Poitiers laboratory currently offers a full range of bioanalytical services for both small molecules and biologics, including mass spectrometry, immunoassays and cell-based assays. The expansion at the site follows SGS's recent announcements of investment and expansion of services at its Lincolnshire, IL, Geneva and Mississauga, Canada laboratories.

With 18 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network to deliver solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the biopharmaceutical market, SGS also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD (pharmacokinetic/pharmacodynamic) modeling and simulation, pharmacovigilance and regulatory consultancy.

For further information, please contact:

Jessica Martin
Global Head of Marketing, Life Sciences
SGS
t: +1 847 821 8900
www.sgs.com/lifescience

Richard Kerns
President 
NEPR
t: +44 (0) 161 728 5880

About SGS

SGS is the world's leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 95,000 employees, SGS operates a network of over 2,400 offices and laboratories around the world.